Assessing the Influence of Proton Pump Inhibitors on Clinical Outcomes in Hormone Receptor-Positive Metastatic Breast Cancer Patients Receiving CDK4/6 Inhibitors: Evidence from a Ribociclib-Dominant Cohort.

Enes Erul, Nejat Emre Öksüz, Erman Akkus, Pınar Kubilay Tolunay, Elif Berna Köksoy, Hatime Arzu Yasar

Abstract read

In one paragraph

Article in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Enes ErulDivision of Medical Oncology, Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara 06620, Türkiye.ORCID 0000-0002-2487-2087

Nejat Emre ÖksüzDivision of Medical Oncology, Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara 06620, Türkiye.

Erman AkkusDivision of Medical Oncology, Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara 06620, Türkiye.ORCID 0000-0002-7531-7817

Pınar Kubilay TolunayDivision of Medical Oncology, Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara 06620, Türkiye.

Elif Berna KöksoyDivision of Medical Oncology, Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara 06620, Türkiye.

Hatime Arzu YasarDivision of Medical Oncology, Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara 06620, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AminopyridinesBreast NeoplasmsProton Pump InhibitorsPurinesAdultAgedCohort StudiesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6FemaleHumansMiddle AgedPiperazinesProgression-Free SurvivalPyridinesReceptors, ProgesteroneAminopyridinesCDK4 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6palbociclibPiperazinesProton Pump InhibitorsPurinesPyridinesReceptors, ProgesteroneribociclibbioavailabilityCDK4/6 inhibitorsdrug–drug interactionsendocrine therapyHR-positive/HER2-negative metastatic breast cancerpalbociclibprogression-free survivalproton pump inhibitorsreal-world observational studyribociclib

Identifiers

PMID41303797

DOI10.3390/medicina61111960

PMCPMC12654086

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.